Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01197170 · ClinicalTrials.gov registry record · Phase 1
Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance
A Phase 1 study of Solid Tumors and Advanced Cancer, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 277
- Enrollment target
- 1
- Study location
NCT01197170 is a Phase 1 study of Solid Tumors and Advanced Cancer that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 277 participants, roughly in line with the 282-participant average among 125 other Solid Tumors trials with a reported enrollment target. The trial reports 1 study location across 1 state.
The verdict
NCT01197170, a Phase 1 study of Solid Tumors and Advanced Cancer, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 277 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical research study to find the highest tolerated dose of anastrozole alone or in combination with either everolimus (Afinitor), sorafenib (Nexavar), erlotinib (Tarceva), fulvestrant (Faslodex), or bevacizumab (Avastin) that can be given to patients with advanced cancer. The safety of these drug combinations will also be studied.
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Anastrozole
- DRUG Everolimus
- DRUG Sorafenib
- DRUG Erlotinib
Study Locations (1)
Texas
- University of Texas MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 277 participants |
| Start Date | 2010-09-07 |
| Est. Completion | 2021-01-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01197170
The ClinicalTrials.gov registry entry for NCT01197170 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 277 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 282-participant average among 125 other Solid Tumors trials with a reported enrollment target. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Solid Tumors appearing as the primary indexed condition, and to 5 interventions - of which Bevacizumab is the first listed.
NCT01197170 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT01197170 about?
NCT01197170 is a clinical study titled "Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance". The goal of this clinical research study to find the highest tolerated dose of anastrozole alone or in combination with either everolimus (Afinitor), sorafenib (Nexavar), erlotinib (Tarceva), fulvestrant (Faslodex), or bevacizumab (Avastin) that can be given to patients with advanced cancer. The saf...
What is the current status of trial NCT01197170?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 277 participants. The study started on 2010-09-07. Estimated completion is 2021-01-13.
What conditions does trial NCT01197170 study?
This clinical trial studies the following conditions: Solid Tumors, Advanced Cancer.
What interventions are being tested in trial NCT01197170?
The interventions under investigation include: Bevacizumab (DRUG), Anastrozole (DRUG), Everolimus (DRUG), Sorafenib (DRUG), Erlotinib (DRUG).
Who is sponsoring clinical trial NCT01197170?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01197170 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of INCB123667 in Subjects With Advanced Solid Tumors
RECRUITING · Phase 1
-
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
RECRUITING · Phase 1
-
Study of AUBE00 in Patients With Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.